WilliamAbramovitsMD

Dermatology • Dallas, TX

Acne & Rosacea, Cosmetic Dermatology, Dermatologic Surgery, Pediatric Dermatology

Owner, Investigator - DERMATOLOGY TREATMENT & RESEARCH CENTER

Join to view full profile

Dr. Abramovits is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Abramovits' full profile

Already have an account?

Office
5310 Harvest Hill Rd
#160
Dallas, TX 75230
Phone+1 972-661-2729

Fax+1 972-661-0227
Is this information wrong?

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Dermatology, 1977 - 1979
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1976 - 1977
University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1974 - 1975
University of Texas Health Science Center at HoustonInternship, Transitional Year, 1973 - 1974
Central University of VenezuelaClass of 1972

Certifications & Licensure

TX State Medical License 1989 - 2025
OK State Medical License 1976 - 1990
American Board of Dermatology Dermatology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Compulink Advantage EHR, Compulink, 2012

Clinical Trials

Safety, Pharmacokinetics, and Efficacy Study of NB-001 to Treat Recurrent Herpes Labialis Start of enrollment: 2007 Feb 01
Completed
Phase 2
Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis Start of enrollment: 2010 Apr 01
Completed
Phase 2
Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea Start of enrollment: 2010 Aug 01
Completed
Phase 2
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea Start of enrollment: 2011 May 01
Completed
Phase 3
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis Start of enrollment: 2019 Aug 12
Active, not recruiting
Phase 3
Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis. Start of enrollment: 2020 Feb 03
Completed
Phase 3
A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3) Start of enrollment: 2021 May 04
Completed
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Seborrheic Keratosis: A Not So Humble Skin Lesion.
William Abramovits, Sijil Patel, Kimberly Dawn Vincent, Aditya Gupta> ;Skinmed. 2023 Jan 1
15 citations
Spesolimab, an anti-interleukin-36 receptor antibody, in patients with moderate-to-severe atopic dermatitis: Results from a multicentre, randomized, double-blind, plac...
Robert Bissonnette, William Abramovits, Étienne Saint-Cyr Proulx, Patricia Lee, Emma Guttman-Yassky, Elizabeta Zovko, Ralf Sigmund, Joanne Willcox, Thomas Bieber> ;Journal of the European Academy of Dermatology and Venereology. 2023 Mar 1
13 citations
Pharmacokinetics, Safety, Efficacy, and Biomarker Profiles During Nemolizumab Treatment of Atopic Dermatitis in Adolescents.
Robert Sidbury, Sady Alpizar, Vivian Laquer, Sunil Dhawan, William Abramovits, Luca Loprete, Jayendar Kumar Krishnaswamy, Faiz Ahmad, Zarif Jabbar-Lopez, Christophe Pi...> ;Dermatology and Therapy. 2022 Mar 1
JUBLIA (Efinaconazole 10% Solution) in the Treatment of Pediatric Onychomycosis.
Aditya K. Gupta, Maanasa Venkataraman, William Abramovits, Eric Guenin> ;Skinmed. 2021 Jan 1
1 citations
Amzeeq (minocycline foam 4%) for topical treatment of acne vulgaris.
Aditya K. Gupta, Anthony Bruce, Kimberly Dawn Vincent, William Abramovits> ;Skinmed. 2020 Dec 1
Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam for Plaque Psoriasis in Adolescents Aged 12-17 Years.
William Abramovits, Joyce M.C. Teng, Kimberly Dawn Vincent, Aditya K. Gupta> ;Skinmed. 2020 Aug 1
AKLIEF (Trifarotene 0.005% [50 μg/g] Cream) for Topical Treatment of Acne Vulgaris
Aditya K. Gupta, Anthony Bruce, William Abramovits, Kimberly Dawn Vincent> ;Skinmed. 2020 May 1
ARAZLO (Tazarotene 0.045%) Lotion for Topical Treatment of Acne Vulgaris.
Aditya K. Gupta, Anthony Bruce, William Abramovits> ;Skinmed. 2020 Mar 1
Efficacy and Safety of Systemic Treatments for Skin and Joint Manifestations in Patients With Psoriasis.
William Abramovits, Joel Schlessinger> ;Journal of Drugs in Dermatology. 2020 Mar 1
1 citations
DUOBRII™ (Halobetasol Propionate and Tazarotene) Lotion for Topical Use: A Newly Approved Combination Corticosteroid and Retinoid Topical Treatment of Plaque Psoriasis...
Aditya K. Gupta, Robin P Love, William Abramovits, Kimberly Dawn Vincent> ;Skinmed. 2019 Sep 9
Eskata® (Hydrogen Peroxide 40%)-A Treatment for Seborrheic Keratosis.
Aditya K. Gupta, Sarah G Versteeg, William Abramovits, Sijil Patel, Kimberly Dawn Vincent> ;Skinmed. 2019 Jul 1
19 citations
Conceptual Model to Illustrate the Symptom Experience and Humanistic Burden Associated With Atopic Dermatitis in Adults and Adolescents.
Laura Grant, Lotte Seiding Larsen, Claire Trennery, Jonathan I. Silverberg, William Abramovits, Eric L. Simpson, Jean-François Stalder, Jean Paty, Julie Hahn-Pedersen,...> ;Dermatitis. 2019 Jul 1
1 citations
Dupixent® (Dupilumab): A Newly Approved Interleukin-4 Receptor Antagonist for the Treatment of Atopic Dermatitis in Pediatric Patients.
Aditya K. Gupta, Robin P Love, William Abramovits, Kimberly Dawn Vincent> ;Skinmed. 2019 May 29
2 citations
Tremfya™ (Guselkumab).
William Abramovits, Ali Wiqas, Kimberly Dawn Vincent, Sarah G Versteeg, Aditya K Gupta> ;Skinmed. 2019 Mar 19
2 citations
Conceptual issues in dermatology and medicine: Where do nonphysician practitioners rightfully belong-a dermatologist's perspective.
William Abramovits> ;Clinics in Dermatology. 2019 Jan 1
25 citations
T-cell-mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib ...
Kevin L. Winthrop, Neil J. Korman, William Abramovits, Scott T. Rottinghaus, Huaming Tan, Annie Gardner, Geoffrey Mukwaya, Mandeep Kaur, Hernan Valdez> ;Journal of the American Academy of Dermatology. 2018 Jun 1
Odomzo(Sonidegib).
Aditya K Gupta, Rachel R Mays, William Abramovits, Kimberly Dawn Vincent> ;Skinmed. 2018 Feb 1
2 citations
Ilumya® (Tildrakizumab): A Newly Approved Interluekin-23 Antagonist for the Treatment of Plaque Psoriasis.
Aditya K. Gupta, Sarah G Versteeg, William Abramovits, Kimberly Dawn Vincent> ;Skinmed. 2018 Jan 1
4 citations
Cimzia™ (Certolizumab Pegol).
William Abramovits, Ali Wiqas, Kimberly Dawn Vincent, Sarah G Versteeg, Aditya K. Gupta> ;Skinmed. 2018 Dec 21
3 citations
Bavencio® (Avelumab)-A Newly Approved Anti-PD-L1 IgG1 Antibody.
Aditya K. Gupta, Sarah G Versteeg, William Abramovits, Kimberly Dawn Vincent> ;Skinmed. 2018 Jun 1
1 citations
Brodalumab (Siliq®): A Treatment for Plaque Psoriasis.
Aditya K. Gupta, Sarah Versteeg Versteeg, William Abramovits, Kimberly Dawn Vincent> ;Skinmed. 2017 Aug 1
31 citations
Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry.
Alan Menter, Diamant Thaçi, Jashin J. Wu, William Abramovits, Francisco A. Kerdel, Dilek Arikan, Dianlin Guo, Arijit Ganguli, Mareike Bereswill, Anne Camez, Wendell C....> ;Dermatology and Therapy. 2017 Aug 16
19 citations
Treating Alopecia Areata: Current Practices Versus New Directions
Aditya K. Gupta, Jessie Carviel, William Abramovits> ;American Journal of Clinical Dermatology. 2017 Feb 1
1 citations
AMELUZ™ (BF-200 ALA).
Aditya K. Gupta, Sarah G Versteeg, William Abramovits> ;Skinmed. 2017 Jan 1
1 citations
Ozenoxacin Cream, 1% - Topical Treatment of Impetigo.
Aditya K. Gupta, Sarah G Versteeg, William Abramovits> ;Skinmed. 2017 Feb 1
Join now to see all

Journal Articles

Conceptual Issues in Dermatology and Medicine: Where Do Nonphysician Practitioners Rightfully Belong—a Dermatologist’s Perspective
William Abramovits, MD, ScienceDirect